Analysts See More Than 77% Upside for Eupraxia Pharmaceuticals (EPRX), Here's Why

​Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) is one of the Best Up and Coming Canadian Stocks to Buy. Analysts see more than 77% upside for Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX). This bullish sentiment comes after the clinical-stage biotechnology company reported promising results from its Phase 2b RESOLVE trial for eosinophilic esophagitis on November 13.

​The additional 52-week follow-up data from the RESOLVE trial showed all patients in Cohort 6 maintained symptom improvement at week 52 with an average reduction in SDI scores of -3.7 (-58%). Management noted that patients reaching 52 weeks in the trial showed durable symptom relief, which is clinically meaningful.

​Following the announcement, on November 14, Kristen Kluska from Cantor Fitzgerald reiterated a Buy rating on Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) with a price target of C$15.38, reflecting more than 76% upside from the current level.

​Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) is a clinical-stage biotechnology company developing locally delivered, extended-release drug products using its proprietary DiffuSphere technology.

While we acknowledge the potential of EPRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.